07:05 EST Krystal Biotech (KRYS) sees FY25 non-GAAP R&D, SG&A expense $145M-$155M
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech reports Q3 EPS $2.66, consensus $1.12
- KRYS Earnings this Week: How Will it Perform?
- Krystal Biotech’s Promising Lung Cancer Study: A Potential Game-Changer?
- Krystal Biotech’s KB407 Study: A Promising Step for Cystic Fibrosis Treatment
- Krystal Biotech’s Innovative Approach to Treating Alpha-1 Antitrypsin Deficiency: A Clinical Update